The estimated Net Worth of Christopher R. Fenimore is at least $20.9 Million dollars as of 28 August 2024. Mr. Fenimore owns over 5,680 units of Regeneron Pharmaceuticals stock worth over $28,536 and over the last 7 years he sold REGN stock worth over $20,833,774. In addition, he makes $0 as Vice President and Controller at Regeneron Pharmaceuticals.
Christopher has made over 25 trades of the Regeneron Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 5,680 units of REGN stock worth $6,846,274 on 28 August 2024.
The largest trade he's ever made was exercising 13,500 units of Regeneron Pharmaceuticals stock on 20 August 2021 worth over $2,418,255. On average, Christopher trades about 3,499 units every 71 days since 2017. As of 28 August 2024 he still owns at least 25 units of Regeneron Pharmaceuticals stock.
You can see the complete history of Mr. Fenimore stock trades at the bottom of the page.
Christopher R. Fenimore serves as Vice President, Controller of the Company since March 2017. From January 2017 to March 2017, he served as Vice President, Deputy Controller, and previously served as Vice President, Financial Planning from January 2012 to December 2016. Prior to joining the Company in 2003, he was Vice President, Finance at Mojave Therapeutics, Inc. Mr. Fenimore’s prior experience includes working as a supervising senior accountant at KPMG, as well as healthcare industry- focused venture capital and investment banking roles. Mr. Fenimore holds an M.A. in Biotechnology from Columbia University, an M.B.A. in Professional Accounting from Rutgers Business School, and a B.A. in Economics from Rutgers University. Mr. Fenimore is a Certified Public Accountant in the State of New York.
Christopher Fenimore is 49, he's been the Vice President and Controller of Regeneron Pharmaceuticals since 2017. There are 22 older and 2 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis, and Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: